Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
To determine the safety and tolerability of Entinostat in combination with Enzalutamide in metastatic castrate resistant prostate cancer
Prostate Adenocarcinoma
DRUG: Entinostat|DRUG: Enzalutamide
Determination of a suitable dose of Entinostat in combination with Enzalutamide, Number of participants who experience an adverse event assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, 18 months
Progression Free Survival, Number of participants who survive without disease progression, 3 years|Changes in circulating T cell subtype, peripheral blood mononuclear cell (PBMC) H3 acetylation, and phenotype of circulating Tregs, Analysis of immunomodulatory effects of Entinostat, 18 months
This study is designed to determine the safety and tolerability of Entinostat with Enzalutamide for treatment of patients with castration-resistant prostate cancer. There will be two dose levels of Entinostat in combination with same dose of Enzalutamide. Patients will be followed during treatment and 1 month post discontinuation.